SLC5A2 and chronic kidney disease: SGLT2 inhibitors have become well-known for their beneficial effects on glycemic control, reducing cardiovascular risk, slowing the progression of chronic kidney disease (CKD), and lowering the risk of kidney failure in individuals with T2D [8].